TKPHF
What one share of Takeda Pharmaceutical Company Limited holds
Pharmaceutical Preparations
We are a global R&D-driven biopharmaceutical company focused on discovering and delivering life-transforming treatments in our core therapeutic areas of gastrointestinal and inflammation, neuroscience and oncology, as well as through our plasma-derived therapies and vaccines business.
Takeda Pharmaceutical Company Limited’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $9.51 |
|---|---|
| Profit | −$0.32 |
| Capex (buildings and equipment) | $0.37 |
| Free cash flow | $1.83 |
| Dividends | $0.66 |
| Cash and investments | $1.18 |
| Debt | $9.64 |
| Book value | $14.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $10.20 | $0.68 | $0.36 | $1.18 | — | $11.06 |
| 2018 | $10.16 | $1.07 | $0.38 | $1.78 | — | $11.83 |
| 2019 | $9.78 | $0.63 | $0.36 | $1.17 | — | $14.96 |
| 2020 | $9.67 | $0.13 | $0.37 | $1.59 | — | $13.93 |
| 2021 | $9.58 | $1.13 | $0.33 | $2.70 | — | $14.83 |
| 2022 | $10.08 | $0.65 | $0.35 | $2.82 | — | $14.79 |
| 2023 | $9.49 | $0.75 | $0.33 | $1.97 | — | $15.13 |
| 2024 | $9.35 | $0.32 | $0.38 | $1.19 | — | $15.20 |
| 2025 | $9.37 | $0.22 | $0.41 | $1.75 | — | $14.54 |
| 2026 | $9.51 | −$0.32 | $0.37 | $1.83 | — | $14.68 |